Article info

Original research
Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

Authors

  1. Correspondence to Dr Paolo Antonio Ascierto; paolo.ascierto{at}gmail.com
View Full Text

Citation

Mallardo D, Giannarelli D, Vitale MG, et al
Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

Publication history

  • Accepted July 23, 2022
  • First published November 24, 2022.
Online issue publication 
November 24, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.